Avid: Quick and early
There is keen interest in developing early diagnostics for degenerative diseases where early therapeutic intervention is likely to provide the greatest benefit but diagnosis is still largely dependent on an assessment of symptoms. Avid Radiopharmaceuticals Inc. is developing a pipeline of targeted radioactive small molecules that it hopes may one day allow for routine early screening for Alzheimer's disease, Parkinson's disease/dementia with Lewy bodies (DLB) and diabetes.
Avid (Philadelphia, Penn.) has